echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Blood: The endogenous TCR expression of CD19-CAR-T cells?

    Blood: The endogenous TCR expression of CD19-CAR-T cells?

    • Last Update: 2020-06-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    Anti-CD19 encrusted antigen receptor (CAR) T cells exhibit significant anti-leukemia activity in B precursor acute lymphoblastic leukemia (ALL)A foreign, HLA mismatched off-the-shelf third-generation donor may provide ideal adaptability to the effect cells, but there is a risk of graft-resistant host disease (GVHD)Knocking out endogenous T-cell receptors (CRRs) of CD19-CAR-T cells may be a promising solutionIn this study, the researchers transduced the TC Rb chain with CRISPR/Cas9 medial in the primary T cells, combined with a second-generation retrovirus CAR containing a 4-1BB co-stimulating domainAfter the above treatment, the researchers obtained a highly functional TCR-KO-CAR-T cell group with strong activation (CD25, IFN-mouse serum), proliferation and specific killings for CD19 target recognitionTCR-KO-CAR-T cells have a balanced phenotype of central memory and effect memory T cellsKnocking out T-cell endogenous TCR strongly reduces the foreign reactivity compared to T cells expressing TCRIn an all-child xenotransplant model, TCR-KO-CAR-T cells clearly controlled the burden of CD19 plus leukemia, improving the survival rate of transplanted small cellsHowever, co-expression of endogenous TCR and CAR can provide excellent persistence of T cells and significantly prolong the inviviable control time of leukemia, as demonstrated in the second in vivo model using NALM6 leukemia cellsThe above results suggest that endogenous TCR plays an important role in reaction lifeIn summary, the anti-CD19 CAR T cells of the CRISPR/Cas9-mediated TCR KO are highly promising choices for non-matching third-party secondary T-cell transplantation, which has high anti-leukemia function without all-out allogeneic reactions, but has better in vivo response persistence when presented with endogenous TCR expression
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.